These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 28293776)

  • 61. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
    Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
    J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study.
    Brinkmann GH; Norvang V; Norli ES; Grøvle L; Haugen AJ; Lexberg ÅS; Rødevand E; Bakland G; Nygaard H; Krøll F; Widding-Hansen IJ; Bjørneboe O; Thunem C; Kvien T; Mjaavatten MD; Lie E
    Semin Arthritis Rheum; 2019 Apr; 48(5):808-814. PubMed ID: 30205983
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice.
    Linde L; Sørensen J; Østergaard M; Hetland ML
    J Rheumatol; 2013 Sep; 40(9):1479-86. PubMed ID: 23818719
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea.
    Song JJ; Song YW; Bae SC; Cha HS; Choe JY; Choi SJ; Kim HA; Kim J; Kim SS; Lee CK; Lee J; Lee SH; Lee SS; Lee SK; Lee SW; Park SH; Park W; Shim SC; Suh CH; Yoo B; Yoo DH; Yoo WH
    J Korean Med Sci; 2018 Dec; 33(52):e346. PubMed ID: 30584418
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values.
    Chung MK; Park B; Kim IJ; Cho SK; Kim D; Sung YK; Choi CB; Choe JY; Chung WT; Hong SJ; Kim TH; Koh E; Lee SS; Yoon BY; Park H; Bae SC; Lee J
    Int J Rheum Dis; 2019 May; 22(5):852-859. PubMed ID: 30677239
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs.
    Valleala H; Korpela M; Hienonen-Kempas T; Immonen K; Lähteenmäki J; Uusitalo T; Komulainen R; Möttönen T; Hannonen P
    J Clin Rheumatol; 2015 Jan; 21(1):24-30. PubMed ID: 25539430
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry.
    Steunebrink LM; Versteeg GA; Vonkeman HE; Ten Klooster PM; Kuper HH; Zijlstra TR; van Riel PL; van de Laar MA
    Arthritis Res Ther; 2016 Mar; 18():60. PubMed ID: 26956382
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
    Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
    Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
    Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
    Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.
    Cárdenas M; de la Fuente S; Castro-Villegas MC; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérrez J; Escudero-Contreras A; Del Prado JR; Collantes-Estévez E; Font P
    Rheumatol Int; 2016 Dec; 36(12):1627-1632. PubMed ID: 27778067
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Do radiographic joint damage and disease activity influence functional disability through different mechanisms? Direct and indirect effects of disease activity in established rheumatoid arthritis.
    Nair SC; Bijlsma JW; van der Werf JH; van der Veen MJ; Linn-Rasker SP; Vreugdenhil S; Lafeber FP; Welsing PM
    J Rheumatol; 2013 Sep; 40(9):1505-12. PubMed ID: 23818710
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.
    Haugeberg G; Hansen IJ; Soldal DM; Sokka T
    Arthritis Res Ther; 2015 Aug; 17(1):219. PubMed ID: 26290061
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Biologics initiation in moderate versus severe rheumatoid arthritis: real-world experience from a Canadian registry.
    Guo N; Li X; Movahedi M; Cesta A; Bombardier C
    Clin Exp Rheumatol; 2024 May; 42(5):1067-1074. PubMed ID: 38372710
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A comprehensive care program achieves high remission rates in rheumatoid arthritis in a middle-income setting. Experience of a Center of Excellence in Colombia.
    Santos-Moreno P; Alvis-Zakzuk NJ; Villarreal-Peralta L; Carrasquilla-Sotomayor M; Paternina-Caicedo A; Alvis-Guzmán N
    Rheumatol Int; 2018 Mar; 38(3):499-505. PubMed ID: 29248952
    [TBL] [Abstract][Full Text] [Related]  

  • 77. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis.
    Rubbert-Roth A; Aletaha D; Devenport J; Sidiropoulos PN; Luder Y; Edwardes MD; Jacobs JWG
    Rheumatology (Oxford); 2021 Feb; 60(2):682-691. PubMed ID: 32844216
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
    Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.